| Hazard Information | Back Directory | [Uses]
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity[1][2][3]. | [in vivo]
Acetyl Gastric Inhibitory Peptide (human) (25 nmol/kg; i.p.; single dose) shows resistance to plasma dipeptidylpeptidase IV degradation, resulting in enhanced biological activity and improved antidiabetic potential in vivo[1].
| Animal Model: | Obese hyperglycaemic (ob/ob) mice[1] | | Dosage: | 25 nmol/kg | | Administration: | Intraperitoneal injection; single dose | | Result: | Lowered individual glucose values at 60 min together with the areas under the curve for glucose compared to native GIP. |
| [References]
[1] O'Harte FP, et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia. 2002 Sep;45(9):1281-91. DOI:10.1007/s00125-002-0894-6
[2] Gault Victor A, et al. GIP peptide analogues for treatment of diabetes, insulin resistance and obesity: World Intellectual Property Organization, WO2005082928[P]. 2005-12-01.
[3] O'Harte, et al. Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function: World Intellectual Property Organization, WO2007028632[P].2007-03-15. |
|
|